The University of Colorado-Denver received a $375,134 Project Grant under the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) to investigate a novel approach to reduce the accumulation of chemotherapeutic nanomedicines in healthy tissues and improve their efficacy against tumors. The research aims to exploit the innate immune response of epithelial tissue tightening, triggered by the cytokine IFN-λ, to limit off-target drug deposition while enhancing delivery to tumors. The project will characterize the tightening response and its effects on organ and skin toxicity, with the goal of identifying conditions to minimize adverse effects while allowing more aggressive dosing of chemotherapies like liposomal doxorubicin. The researchers will explore these effects in mouse models of ovarian cancer and conduct immune profiling to assess potential synergistic benefits. This 5-year grant, awarded on March 1, 2025, supports the university's expertise in cancer research and nanomedicine development.
Generated 3/18/25, 5:16 AM